Unknown PHASE2 INTERVENTIONAL 1-arm NCT01679327

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Sponsor: Chinese Academy of Medical Sciences

Interventions 5-FU Bevacizumab Calcium folinate (CF) Oxaliplatin Xeloda

Updated 8 times since 2017 Last updated: Sep 5, 2012 Started: Mar 31, 2012 Primary completion: Jun 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01679327, this PHASE2 trial focuses on Colorectal Cancer and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE2
Jan 2021 — Dec 2022 [monthly]

Unknown Status PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China